文献速递核素与放射性配体治疗肿瘤 PET/CT

蛋白功能化且内禀放射性标记的[188Re]ReOx纳米颗粒:通过同步放疗与光热效应推进癌症治疗

Protein-functionalized and intrinsically radiolabeled [188Re]ReOx nanoparticles: advancing cancer therapy through concurrent radio-photothermal effects.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2025-01-25

研究合成人血清白蛋白包裹的氧化铼纳米颗粒([188Re]ReOx-HSA NPs),在B16F10黑色素瘤细胞及C57BL/6荷瘤小鼠中验证其同步放疗与光热治疗潜力。纳米颗粒粒径4-6 nm,激光照射后活细胞不足20%,瘤内注射后SPECT/CT显示均匀剂量分布,约1.85 MBq剂量联合激光照射显著抑制肿瘤生长。

要点

  • 合成[188Re]ReOx-HSA NPs粒径4-6 nm,具高胶体与放射化学稳定性。
  • B16F10细胞经808 nm激光照射后活细胞不足20%。
  • 约1.85 MBq瘤内注射联合激光照射显著抑制小鼠肿瘤生长。

核心结论

  • 内禀放射性标记的[188Re]ReOx-HSA NPs兼具高光热效应与 favorable 核衰变特征,适用于同步放疗/光热治疗,作者认为其具有临床转化前景。

研究设计与样本

  • 研究为实验性纳米颗粒开发与临床前评估,包括体外细胞实验和C57BL/6荷瘤小鼠体内研究。

主要发现

  • [188Re]ReOx-HSA NPs粒径4-6 nm,具高胶体与放射化学稳定性。
  • B16F10细胞与[188Re]ReOx-HSA NPs孵育后经808 nm激光照射,活细胞不足20%。
  • 瘤内注射后SPECT/CT成像与放射自显影显示放射性纳米颗粒在肿瘤体积内剂量分布均匀并滞留。
  • 小鼠模型中约1.85 MBq剂量[188Re]ReOx-HSA NPs联合同步激光照射显著抑制肿瘤生长,显示放疗与光热治疗的协同获益。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Enhancing therapeutic effectiveness is crucial for translating anticancer nanomedicines from laboratory to clinical settings. In this study, we have developed radioactive rhenium oxide nanoparticles encapsulated in human serum albumin ([188Re]ReOx-HSA NPs) for concurrent radiotherapy (RT) and photothermal therapy (PTT), aiming to optimize treatment outcomes. METHODS: [188Re]ReOx-HSA NPs were synthesized by a controlled reduction of 188ReO4- in HSA medium and extensively characterized. The anticancer effect of [188Re]ReOx-HSA NPs was demonstrated in vitro in murine melanoma (B16F10) cell line. In vivo SPECT/CT imaging, autoradiography and biodistribution studies were performed after intratumoral injection of [188Re]ReOx-HSA NPs in melanoma tumor-bearing C57BL/6 mice. The potential of [188Re]ReOx-HSA NPs for combined RT and PTT treatment was also demonstrated in the aforesaid mice model. RESULTS: [188Re]ReOx-HSA NPs (size 4-6 nm) were synthesized with high colloidal and radiochemical stability. Upon laser (808 nm) exposure on B16F10 cells incubated with [188Re]ReOx-HSA NPs, only < 20% of cells were alive demonstrating high therapeutic efficacy under in vitro settings. Uniform dose distribution and retention of the radiolabeled NPs in the tumor volume were observed via SPECT/CT imaging and autoradiography studies. Tumor growth in mice model was significantly arrested with ~ 1.85 MBq dose of [188Re]ReOx-HSA NPs and simultaneous laser irradiation, demonstrating synergistic benefit of RT and PTT. CONCLUSIONS: These results demonstrate that intrinsically radiolabeled [188Re]ReOx-HSA NPs having unique features such as high photothermal effects and favorable nuclear decay characteristics for combined RT/PTT, hold great promise for clinical translation.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Ghosh S, Guleria A, Patra S, et al. Protein-functionalized and intrinsically radiolabeled [188Re]ReOx nanoparticles: advancing cancer therapy through concurrent radio-photothermal effects. Eur J Nucl Med Mol Imaging. 2025. PMID: 39856453. doi:10.1007/s00259-025-07074-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。